Bristol Myers Squibb Company (NYSE:BMY) Has Increase in Shorts

September 17, 2017 - By Stephen Andrade

 Bristol Myers Squibb Company (NYSE:BMY) Has Increase in Shorts

Investors sentiment decreased to 0.97 in Q4 2016. Its down 0.16, from 1.13 in 2016Q3. It fall, as 86 investors sold Bristol-Myers Squibb Co shares while 529 reduced holdings. 126 funds opened positions while 468 raised stakes. 1.14 billion shares or 1.92% more from 1.12 billion shares in 2016Q3 were reported.
King Wealth Mgmt Gru Limited Co holds 0.19% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY) for 7,081 shares. Bath Savings Com has 15,773 shares for 0.28% of their portfolio. 4,125 were reported by West Oak Cap Llc. The Virginia-based Old Point Tru N A has invested 0.23% in Bristol-Myers Squibb Co (NYSE:BMY). Spears Abacus Advsr Ltd Liability Company reported 3,730 shares. Da Davidson Co invested 0.22% of its portfolio in Bristol-Myers Squibb Co (NYSE:BMY). Burke Herbert Savings Bank Tru accumulated 0.7% or 13,170 shares. First Bancshares Sioux Falls stated it has 8,039 shares or 1.9% of all its holdings. The Georgia-based Atlanta Grp has invested 0.56% in Bristol-Myers Squibb Co (NYSE:BMY). Washington holds 0.08% in Bristol-Myers Squibb Co (NYSE:BMY) or 19,977 shares. Fin Counselors has invested 0.37% in Bristol-Myers Squibb Co (NYSE:BMY). Northern Capital Mngmt Lc has 0.37% invested in Bristol-Myers Squibb Co (NYSE:BMY) for 14,975 shares. Tortoise Inv Ltd Liability Corp stated it has 0% in Bristol-Myers Squibb Co (NYSE:BMY). 16,475 were reported by Texas Yale Cap Corp. 8,885 are owned by Rosenblum Silverman Sutton S F Incorporated Ca.

Since March 17, 2017, it had 0 buys, and 2 sales for $3.72 million activity. $1.81M worth of Bristol-Myers Squibb Co (NYSE:BMY) shares were sold by ANDREOTTI LAMBERTO. Schmukler Louis S had sold 5,000 shares worth $282,470.

The stock of Bristol Myers Squibb Company (NYSE:BMY) registered an increase of 1.12% in short interest. BMY’s total short interest was 10.09 million shares in September as published by FINRA. Its up 1.12% from 9.98 million shares, reported previously. With 5.11 million shares average volume, it will take short sellers 2 days to cover their BMY’s short positions.

The stock decreased 0.35% or $0.22 on September 15, reaching $62.48. About 10.41M shares traded or 75.84% up from the average. Bristol-Myers Squibb Co (NYSE:BMY) has declined 23.19% since September 17, 2016 and is downtrending. It has underperformed by 39.89% the S&P500.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The company has market cap of $102.46 billion. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. It has a 22.77 P/E ratio. Small molecule drugs are administered orally in the form of a pill or tablet.

Bristol-Myers Squibb Co (NYSE:BMY) Ratings Coverage

Among 19 analysts covering Bristol-Myers Squibb Company (NYSE:BMY), 6 have Buy rating, 3 Sell and 10 Hold. Therefore 32% are positive. Bristol-Myers Squibb Company had 53 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was upgraded by Piper Jaffray to “Underweight” on Monday, August 24. The rating was maintained by Barclays Capital with “Equal Weight” on Friday, April 29. BMO Capital Markets maintained the shares of BMY in report on Wednesday, August 16 with “Sell” rating. As per Thursday, August 11, the company rating was downgraded by Berenberg. BMO Capital Markets maintained the shares of BMY in report on Wednesday, April 5 with “Market Perform” rating. The company was maintained on Tuesday, March 15 by Jefferies. As per Tuesday, September 29, the company rating was upgraded by UBS. Jefferies maintained Bristol-Myers Squibb Co (NYSE:BMY) rating on Wednesday, August 23. Jefferies has “Buy” rating and $66.0 target. As per Friday, October 28, the company rating was maintained by Deutsche Bank. The firm has “Hold” rating by Jefferies given on Tuesday, June 14.

More notable recent Bristol-Myers Squibb Co (NYSE:BMY) news were published by: which released: “Bristol-Myers Squibb says late-stage cancer drug combination study met …” on September 07, 2017, also with their article: “Bristol-Myers Squibb (BMY) Presents at Morgan Stanley Healthcare Conference …” published on September 12, 2017, published: “Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney …” on September 14, 2017. More interesting news about Bristol-Myers Squibb Co (NYSE:BMY) were released by: and their article: “Bristol-Myers Squibb Is Primed for an Upside Breakout” published on August 31, 2017 as well as‘s news article titled: “Bristol-Myers Squibb Gets Huge Boost In Oncology Program After Trial Stoppage” with publication date: September 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.